Cizzle Biotechnology enters into a new research agreement with the University of York

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that it has entered into a new research agreement with the University of York for the development and validation of molecular tools with potential applications in cancer diagnosis and therapy.

The Company’s wholly owned subsidiary Cizzle Biotechnology Limited was a spin out from the University of York based on original research and development undertaken in laboratories at the University, under the direction of Professor Dawn Coverley. The new agreement extends that relationship and provides seconded staff and access to the University’s state of the art research facilities to support reagent generation work in collaboration with our recently announced Contract Research Organisation (CRO) partner Fairjouney Biologics.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: “We are thrilled to be able to cement our long-standing relationship with the University of York, a member of the Russell Group of research-intensive universities and one of the world’s premier institutions for inspirational and life-changing research.  This new agreement will provide valuable additional resource and capability for developing our blood test for the early detection of lung cancer, and potentially other forms of cancer.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology completes evaluation programme with Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat

    Cizzle Biotech

    Cizzle Biotechnology AGM to be held on 27 June 2022

    Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, have been sent to